Browse history interactively

Page 1

Page 1Revision 1

Page 2

Page 2Revision 2

← Previous editContent deleted Content addedVisualWikitext

Revision as of 11:11, 31 July 2010 editCeliakozlowski (talk | contribs)710 editsmNo edit summary← Previous edit		Latest revision as of 15:17, 24 October 2024 edit undo193.62.194.250 (talk) ChEBI ID added to CHEMBOX identifiers
(28 intermediate revisions by 22 users not shown)
Line 1:		Line 1:
			{{Short description|Analgesic and anti-inflammatory compound}}
	{{chembox
			{{Infobox drug
⚫	|ImageFile=Licofelone_structure.svg
			| Verifiedfields = changed
	|ImageSize=
			| Watchedfields = changed
⚫	|IUPACName=acetic acid
			| verifiedrevid = 376409282
	|OtherNames=
			| drug_name =
	|Section1={{Chembox Identifiers
			| INN =
	| CASNo=156897-06-2
			| type =<!-- empty -->
⚫	| PubChem=133021
		⚫	| IUPAC_name = acetic acid
	| SMILES=CC1(CC2=C(C(=C(N2C1)CC(=O)O)C3=CC=C(C=C3)Cl)C4=CC=CC=C4)C
		⚫	| image = Licofelone_structure.svg
	}}
			| alt =
	|Section2={{Chembox Properties
			| caption =
	| Formula=C<sub>23</sub>H<sub>22</sub>ClNO<sub>2</sub>
			<!-- Clinical data -->
	| MolarMass=379.879 g·mol<sup>−1</sup>
			| pronounce =
	| Appearance=
			| tradename =
	| Density=
			| Drugs.com =
	| MeltingPt=
			| MedlinePlus =
	| BoilingPt=
			| pregnancy_AU = <!-- A/B1/B2/B3/C/D/X -->
	| Solubility=
			| pregnancy_AU_comment =
	}}
			| pregnancy_US = <!-- A/B/C/D/X/N -->
	|Section3={{Chembox Hazards
			| pregnancy_category=
	| MainHazards=
			| routes_of_administration =
	| FlashPt=
			| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
	| Autoignition=
			| legal_AU_comment =
	}}
			| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
			| legal_BR_comment =
			| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
			| legal_DE = <!-- Anlage I, II, III -->
			| legal_NZ = <!-- Class A, B, C -->
			| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
			| legal_US = <!-- OTC/Rx-only/Schedule I, II, III, IV, V -->
			| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
			| legal_status = Investigational
			<!-- Pharmacokinetic data -->
			| bioavailability =
			| protein_bound =
			| metabolism =
			| metabolites =
			| onset =
			| elimination_half-life =
			| duration_of_action =
			| excretion =
			<!-- Identifiers -->
			| CAS_number = 156897-06-2
			| class =
			| ATCvet =
			| ATC_prefix = <!-- 'none' if uncategorised -->
			| ATC_suffix =
			| DrugBank =
			| UNII = P5T6BYS22Y
		⚫	| PubChem=133021
			| ChEMBL = 52854
			| ChEBI = 47532
			| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
			| ChemSpiderID = 117391
			<!-- Chemical and physical data -->
			| C=23|H=22|Cl=1|N=1|O=2
			| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
			| StdInChI = 1S/C23H22ClNO2/c1-23(2)13-19-22(15-6-4-3-5-7-15)21(16-8-10-17(24)11-9-16)18(12-20(26)27)25(19)14-23/h3-11H,12-14H2,1-2H3,(H,26,27)
			| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
			| StdInChIKey = UAWXGRJVZSAUSZ-UHFFFAOYSA-N
	}}		}}
⚫	'''Licofelone''' is a dual ]/] inhibitor<ref name="pmid17704828">{{cite journal |title=The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products |journal=British journal of pharmacology |volume=152 |issue=4 |pages=471–80 |year=2007 |month=October |pmid=17704828 |pmc=2050828 |doi=10.1038/sj.bjp.0707416 |display-authors=3 |author1=Fischer L |author2=Hornig M |author3=Pergola C |author-separator=, |author-name-separator= |last4=Meindl |first4=N |last5=Franke |first5=L |last6=Tanrikulu |first6=Y |last7=Dodt |first7=G |last8=Schneider |first8=G |last9=Steinhilber |first9=D}}</ref><ref name="pmid17015640">{{cite journal |title=Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis |journal=The Journal of pharmacology and experimental therapeutics |volume=320 |issue=1 |pages=108–16 |year=2007 |month=January |pmid=17015640 |doi=10.1124/jpet.106.110361 |url=http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=17015640 |display-authors=3 |author1=Vidal C |author2=Gómez-Hernández A |author3=Sánchez-Galán E |author-separator=, |author-name-separator= |last4=González |first4=A |last5=Ortega |first5=L |last6=Gómez-gerique |first6=JA |last7=Tuñón |first7=J |last8=Egido |first8=J}}</ref> being considered as a treatment for ]<ref name="pmid14752172">{{cite journal |author=Alvaro-Gracia JM |title=Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis |journal=Rheumatology (Oxford, England) |volume=43 Suppl 1 |issue= |pages=i21–5 |year=2004 |month=February |pmid=14752172 |doi=10.1093/rheumatology/keh105 |url=http://rheumatology.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=14752172}}</ref> and which is under development by Merckle GmbH with partners Alfa Wassermann and Lacer.
		⚫	'''Licofelone''' is a dual ]/] inhibitor<ref name="pmid17704828">{{cite journal | vauthors = Fischer L, Hornig M, Pergola C, Meindl N, Franke L, Tanrikulu Y, Dodt G, Schneider G, Steinhilber D, Werz O | display-authors = 6 | title = The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products | journal = British Journal of Pharmacology | volume = 152 | issue = 4 | pages = 471–80 | date = October 2007 | pmid = 17704828 | pmc = 2050828 | doi = 10.1038/sj.bjp.0707416 }}</ref><ref name="pmid17015640">{{cite journal | vauthors = Vidal C, Gómez-Hernández A, Sánchez-Galán E, González A, Ortega L, Gómez-Gerique JA, Tuñón J, Egido J | display-authors = 6 | title = Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 320 | issue = 1 | pages = 108–16 | date = January 2007 | pmid = 17015640 | doi = 10.1124/jpet.106.110361 | s2cid = 73105840 }}</ref> that was studied in clinical trials as a treatment for ]<ref name="pmid14752172">{{cite journal | vauthors = Alvaro-Gracia JM | title = Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis | journal = Rheumatology | volume = 43 Suppl 1 | issue = 90001 | pages = i21-5 | date = February 2004 | pmid = 14752172 | doi = 10.1093/rheumatology/keh105 | doi-access = free }}</ref> and which was under ] by Merckle GmbH with partners Alfa Wassermann and Lacer.
⚫	Licofelone is both an analgesic and an anti-inflammatory. Inhibition of 5-LOX may reduce the gastrointestinal toxicity associated with other ], which only inhibit COX (cyclooxygenase). Licofelone is the first drug to inhibit both. It has passed the phase III trials.<ref>http://www.drugdevelopment-technology.com/projects/licofelone/</ref>
		⚫	Licofelone is both an analgesic and an anti-inflammatory. Inhibition of ] (5-LOX) may reduce the gastrointestinal toxicity associated with other ] (NSAID), which only inhibit ] (COX). Licofelone is the first drug to inhibit both.
⚫	==References==
	{{reflist}}
			Phase III trials for ] were conducted in the early 2000s,<ref>{{cite web | url = http://www.drugdevelopment-technology.com/projects/licofelone/ | title = Licofelone – Novel Analgesic and Anti-Inflammatory Agent for Osteoarthritis | access-date = January 12, 2018}}</ref><ref>{{cite journal | vauthors = Wildi LM, Raynauld JP, Martel-Pelletier J, Abram F, Dorais M, Pelletier JP | title = Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI | journal = Annals of the Rheumatic Diseases | volume = 69 | issue = 12 | pages = 2118–24 | date = December 2010 | pmid = 20610445 | doi = 10.1136/ard.2009.127993 | s2cid = 206864399 }}</ref> but results were mixed and the drug has never been submitted for regulatory approval.
⚫	]
		⚫	== References ==
			{{Reflist|2}}
			{{Prostanoid signaling modulators}}
	{{musculoskeletal-drug-stub}}
		⚫	]
			]